Gubra presents 2030 strategy at Investor R&D Event
Bitget2026/10/27 07:08- Gubra will host its Investor R&D Event in London on Oct. 27, 2026, at 13:00 GMT to present its 2030 strategy.
- The strategy targets 8-10 clinical-stage assets by 2030, with 1-2 proprietary drug development candidates nominated annually from 2030 onward.
- Presentations will cover GUB-UCN2's Phase 1/2a clinical program evaluating body composition, muscle volume and physical function.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
Crypto prices
More
